Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 9/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 7/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813394 | 1.00 | HTT (1.00) | HTTSRD5A1SRD5A2LMNAHSD17B10 | |
| SCHEMBL7886516 | 0.89 | HTT (0.80) | HTTSRD5A1SRD5A2LMNABRAF | |
| SCHEMBL22652227 | 0.89 | HTT (0.80) | HTTSRD5A1SRD5A2LMNABRAF | |
| SCHEMBL7886513 | 0.89 | HTT (0.80) | HTTSRD5A1SRD5A2LMNABRAF | |
| SCHEMBL8312277 | 0.85 | HTT (0.73) | HTTSRD5A1SRD5A2LMNAHSD17B10 | |
| SCHEMBL8312278 | 0.85 | HTT (0.73) | HTTSRD5A1SRD5A2LMNAHSD17B10 | |
| SCHEMBL17988347 | 0.82 | HTT (0.70) | HTTLMNAHSD17B10BRAFMAPK3 | |
| SCHEMBL15282381 | 0.79 | SRD5A1 (0.64) | HTTSRD5A1SRD5A2LMNACYP19A1 | |
| SCHEMBL4344365 | 0.77 | HTT (0.62) | HTTLMNAHSD17B10BRAFMAPK3 | |
| SCHEMBL13615452 | 0.77 | HTT (0.62) | HTTLMNAHSD17B10BRAFMAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669070-A | Synthesis method of O- (dialkyl phosphinic group) ketoxime | 成都理工大学 | 2020-01-10 | — | — | CN | claimed |
| CN-105085279-A | Preparation of R-5-chloro-1-aminoindane | WU LING | 2015-11-25 | — | — | CN | claimed |
| CN-102718663-A | Synthesis method of 5-chloro-1-indene amine | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO LTD | 2012-10-10 | — | — | CN | claimed |
| CN-110669070-B | Synthesis method of O- (dialkyl phosphinic group) ketoxime | 成都理工大学 | 2021-08-27 | — | — | CN | disclosed |
| CN-110669070-A | Synthesis method of O- (dialkyl phosphinic group) ketoxime | 成都理工大学 | 2020-01-10 | — | — | CN | disclosed |
| CN-105085279-A | Preparation of R-5-chloro-1-aminoindane | WU LING | 2015-11-25 | — | — | CN | disclosed |
| US-20140088103-A1 | (FUSED RING ARYLAMINO AND HETEROCYCLYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2691388-A1 | (FUSED RING ARYLAMINO AND HETEROCYCLYLAMINO) PYRIMIDYNYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI Pharma, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| CN-102718663-A | Synthesis method of 5-chloro-1-indene amine | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO LTD | 2012-10-10 | — | — | CN | disclosed |
| CN-102718663-A | Synthesis method of 5-chloro-1-indene amine | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO LTD | 2012-10-10 | — | — | CN | disclosed |
| WO-2012135166-A1 | (FUSED RING ARYLAMINO AND HETEROCYCLYLAMINO) PYRIMIDYNYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-6737547-B1 | Compositions containing and methods of using N-acyl-1H-aminoindenes | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-05-18 | — | — | US | disclosed |
| WO-2000038673-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING N-ACYL-1H-AMINOINDENES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088103-A1 | (FUSED RING ARYLAMINO AND HETEROCYCLYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CDK4, MKI67 | HTT 628/4885SRD5A1 1368/4885SRD5A2 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.